GENE ONLINE|News &
Opinion
Blog

Global Expansion between Europe and India of Novel anti-PD-1 mAb Serplulimab

by Sinead Huang
Share To

Shanghai Henlius Biotech, Inc. has entered into a significant collaboration with Intas Pharmaceuticals Limited, an Indian multinational pharmaceutical company, to further expand the reach of its novel anti-PD-1 monoclonal antibody, serplulimab, in Europe and India. This partnership marks a strategic move to provide high-quality treatments for various indications, including small cell lung cancer, in these regions.

Related article: FDA Approves GSK’s PD-1 Medicine for Early-Detected Endometrial Cancer

Expanding Patient Access to Innovative Healthcare Solutions

The collaboration with Intas Pharmaceuticals builds upon a previous agreement between Henlius and Accord Healthcare Ltd., a subsidiary of Intas. Under this previous agreement, Henlius granted exclusive commercialization rights for HLX02 (trastuzumab for injection) in specific regions. Now, with the addition of serplulimab, the partnership deepens, aiming to enhance patient access to innovative healthcare solutions.

Serplulimab has gained recognition for its efficacy and data quality, making it the world’s first anti-PD-1 monoclonal antibody approved for first-line small cell lung cancer treatment. With multiple approvals in China, and the European Medicines Agency’s validation of its marketing application, Henlius aims to accelerate serplulimab’s accessibility worldwide, ultimately improving patient outcomes.

Future Developments and Impact

This collaboration not only broadens the geographical reach of serplulimab but also strengthens Intas Pharmaceuticals’ global oncology portfolio. With the forthcoming launch of serplulimab in Europe and India, both companies are committed to providing advanced biologics, ensuring that patients worldwide have access to high-quality treatments. Henlius plans to continue working with international partners to expand serplulimab’s development and commercialization globally, increasing therapeutic choices for more patients.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
U.S. Government Awards $1.4 Billion to Advance COVID Therapies and Vaccines
2023-08-29
Evotec SE has secured a contract valued at up to $74M from the U.S. Department of Defense to Combat Orthopoxviruses
2023-07-12
LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top